PPD, Inc. and Janssen Pharmaceutica N.V. Collaborate to Develop Compounds for Treatment of Irritable Bowel Syndrome and Bacterial Infections

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

Back to news